The surge in popularity of GLP-1 medications is changing the face of foodservice and retail. Restaurants and bars are re-thinking portion and drink sizes while CPG brands are responding with product ...

X is putting its money where its mouth is. The Elon Musk-owned social media platform just pledged it will give $1 million to the user who creates the most popular long-form post using its newly ...

Once exclusively a treatment for diabetes, GLP-1 medications have gone mainstream — forcing restaurants to adjust to changing appetites and nutrition needs. As GLP-1 medications normalize smaller ...

China recorded the world’s biggest ever trade surplus in 2025, capping off a year in which the world’s largest manufacturer defied US trade pressure by ramping up exports to other global markets. The ...

Larry and Barbara Cook, 82, thought they were doing the right thing by "helping" the FTC. They converted their $1.3 million life savings to bitcoin and gold, which was stolen by scammers. It took them ...

Amazon customers can file a claim to receive a refund for their Prime subscriptions as part of the company's $2.5 billion settlement with the Federal Trade Commission over allegations of deceptive ...

The federal government is withholding more than $10 billion in family and child care assistance money from Illinois and four other states amid concerns about fraud and misuse of the funds, the U.S.

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

Instacart has agreed to pay consumers $60 million to settle a Federal Trade Commission lawsuit claiming the company engaged in deceptive tactics. The agency’s lawsuit asserts Instacart deceived ...

The big picture: Since its debut in 2012, Instacart has faced several controversies related to the pay structure of its workers, tipping policies, and working conditions. The company is now the ...

Obesity is a well-known risk factor for breast cancer development and recurrence, and glucagon-like peptide 1 (GLP-1) receptor agonists have emerged as effective treatments for weight management. At ...